Samuel Mehr
Nuclear Medicine · Omaha, NENPI 1497781801
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Advanced Accelerator Applications accounts for 74.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2019 at $24,649 and has fallen 88.8% since, to $2,763 in 2025.
Across 58 payments — averaging $640.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Advanced Accelerator Applications$28K
- Aurobindo Pharma USA, Inc.$4K
- Novartis$3K
- Bayer$2K
- Siemens Medical Solutions USA, Inc.$351
- Janssen Scientific Affairs, LLC$129
- plus $238 from 12 others
Across 12 payments — averaging $105,244 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$1.1M
- E.r. Squibb & Sons, L.L.C.$89K
- AstraZeneca$69K
What the payments were for
- Consulting fees$10,13527%
- Speaking & faculty fees$20,75756%
- Travel & lodging$4,58512%
- Food & beverage$1,6634%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Advanced Accelerator Applications | 23 | $27,764 |
| Aurobindo Pharma USA, Inc. | 8 | $4,091 |
| Novartis | 2 | $2,728 |
| Bayer | 3 | $1,839 |
| Siemens Medical Solutions USA, Inc. | 5 | $351 |
| Janssen Scientific Affairs, LLC | 4 | $129 |
| Ipsen Biopharmaceuticals, Inc | 1 | $50 |
| Johnson & Johnson | 2 | $30 |
| Astellas Pharma US Inc | 1 | $23 |
| Telix Pharmaceuticals | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Genentech USA, Inc. | 1 | $16 |
| Incyte Corporation | 1 | $14 |
| Pfizer | 1 | $14 |
| Bristol Myers Squibb | 1 | $14 |
| Clovis Oncology, Inc. | 1 | $13 |
| Blue Earth Diagnostics | 1 | $13 |
| Servier Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lutathera$22,546
- Zevalin$4,019
- Xofigo$1,371
- Nubeqa$468
- Biograph Horizon-3R$166
How this compares
Too few nuclear medicine providers in Nebraskato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.